OUP (Osage University Partners)
Venture Capital
Active
Bala-Cynwyd, United States
220
36M
120
14.67
6
0.45
38
- Stages of investment
- Areas of investment
Summary
In 2009 was created OUP (Osage University Partners), which is appeared as VC. The main office of represented VC is situated in the Bala Cynwyd. The fund was located in North America if to be more exact in United States.
Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Artificial Intelligence. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight Receptos, Cardioxyl Pharmaceuticals, Guardant Health.
This organization was formed by Robert Adelson. We also calculated 5 valuable employees in our database.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The top amount of exits for fund were in 2017. The real fund results show that this VC is 16 percentage points less often commits exit comparing to other companies. The typical startup value when the investment from OUP (Osage University Partners) is 50-100 millions dollars. The fund is constantly included in 7-12 deals per year. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. Opposing the other organizations, this OUP (Osage University Partners) works on 9 percentage points less the average amount of lead investments.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the OUP (Osage University Partners), startups are often financed by OrbiMed, BioAdvance, Sutter Hill Ventures. The meaningful sponsors for the fund in investment in the same round are Sutter Hill Ventures, The Column Group, HBM Healthcare Investments AG. In the next rounds fund is usually obtained by General Catalyst, Lux Capital, OrbiMed.
Investor highlights
- Industry focus
- Stage focus
- Geo focus
- Check size
- 1M — 20M
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Last fund
- Fund raised date
- 2021-09-30
Analytics
- Total investments
- 220
- Lead investments
- 6
- Exits
- 38
- Rounds per year
- 14.67
- Follow on index
- 0.45
- Investments by industry
- Biotechnology (123)
- Health Care (86)
- Therapeutics (51)
- Medical (47)
- Pharmaceutical (37) Show 102 more
- Investments by region
-
- United States (211)
- United Kingdom (3)
- Israel (1)
- Singapore (1)
- India (1)
- Peak activity year
- 2017
- Number of Unicorns
- 2
- Number of Decacorns
- 2
- Number of Minotaurs
- 4
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Avg. valuation at time of investment
- 75M
- Group Appearance index
- 0.96
- Avg. company exit year
- 7
- Avg. multiplicator
- 4.42
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Chroma Medicine | 01 Mar 2023 | Biotechnology, Medical, Therapeutics | Early Stage Venture | 135M | United States, Massachusetts, Cambridge |
Nikola Labs Inc. | 21 Feb 2024 | Consumer Electronics, Internet of Things, Industrial Automation, Industrial Manufacturing, Electrical Distribution | Early Stage Venture | 38M | United States, Ohio |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.